SCHEMBL16326833

SCHEMBL16326833

COC(=O)C(CCCCNC(=O)COCCOCCOCCNC(=O)C(CCCNC(=O)COCCOCCOCCN)NC(=O)COCCOCCOCCN)NC(=O)COCCOCCOCCNC(=O)C(CCCCNC(=O)COCCOCCOCCN)NC(=O)COCCOCCOCCN

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 8/20 0.53
▸ SIRT6 Q8N6T7 1/20 0.41
▸ SIRT1 Q96EB6 1/20 0.41
▸ TLR2 O60603 3/20 0.37
▸ NMT2 O60551 1/20 0.37
▸ NMT1 P30419 1/20 0.37
▸ CHRNA1 P02708 1/20 0.35
▸ CHRNG P07510 1/20 0.35
▸ CHRNB1 P11230 1/20 0.35
▸ CHRND Q07001 1/20 0.35
▸ GRIN1 Q05586 1/20 0.35
▸ GRIN2A Q12879 1/20 0.35
▸ C3AR1 Q16581 1/20 0.35
▸ CPB1 P15086 1/20 0.35
▸ CPB2 Q96IY4 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4517738 0.99 GLP1R (0.54) GLP1RSIRT6SIRT1TLR2NMT2
SCHEMBL3484885 0.99 GLP1R (0.54) GLP1RSIRT6SIRT1TLR2NMT2
SCHEMBL3485126 0.92 GLP1R (0.45) GLP1RSIRT6SIRT1TLR2C3AR1
SCHEMBL3485131 0.92 GLP1R (0.45) GLP1RSIRT6SIRT1TLR2C3AR1
SCHEMBL3485672 0.90 GLP1R (0.56) GLP1RSIRT6SIRT1TLR2MEN1
SCHEMBL3485679 0.90 GLP1R (0.56) GLP1RSIRT6SIRT1TLR2MEN1
SCHEMBL17772689 0.87 GLP1R (0.62) GLP1RSIRT6SIRT1TLR2NMT2
SCHEMBL16326830 0.86 GLP1R (0.50) GLP1RMEN1KMT2A
SCHEMBL16076995 0.85 GLP1R (0.58) GLP1RSIRT6SIRT1TLR2
SCHEMBL21166939 0.85 GLP1R (0.55) GLP1RSIRT6SIRT1TLR2NMT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100028939-A1 Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest NOVO NORDISK HEALTHCARE A/G (CH) 2010-02-04 — — US disclosed
US-20100028939-A1 Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest NOVO NORDISK HEALTHCARE A/G (CH) 2010-02-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100028939-A1 Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest GALE, GALNT2, GALNT1 GLP1R 2352/4885SIRT6 1782/4885SIRT1 1927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback